AccuStem Sciences, Inc. 是一家临床阶段的诊断公司,从事医疗执业活动。公司总部位于纽约州纽约市,目前拥有2名全职员工。该公司于2022年3月1日上市。公司致力于开发和商业化一系列基因组检测产品,以支持肿瘤治疗全流程中的决策。公司专注于其专有的基因组检测,包括用于肺部结节患者的MicroRNA特征分类器(MSC)和用于早期乳腺癌患者的StemPrintER。MSC检测是一种包含24个microRNA(miRNA)的检测方法,旨在帮助确定通过低剂量计算机断层扫描(LDCT)筛查发现的肺部结节是良性还是恶性。StemPrintER是一种20个基因的预后检测方法,旨在预测腔内型(ER+/HER2阴性)乳腺癌患者远处复发(DR)的风险。该检测方法旨在测量肿瘤的干细胞性(stemness),即肿瘤表现得像干细胞的程度,这可能表明癌症复发或对标准治疗产生耐药性的可能性,最终影响患者多学科护理团队的管理方式。
ACUT stock price ended at $0.63 on 星期五, after rising 10.53%
On the latest trading day Feb 06, 2026, the stock price of ACUT rose by 10.53%, climbing from $0.57 to $0.63. During the session, the stock saw a volatility of 10.53%, with prices oscillating between a daily low of $0.57 and a high of $0.63. Notably, trading volume dropped by 234 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 658 shares were traded, equating to a market value of approximately $10.1M.